GLP-1 sourcing is a patient safety issue.

Compounded GLP-1 medications have made genuinely effective treatment accessible to far more patients. That is a good thing. But the rapid growth of the market has also created a supply chain that ranges from rigorous to reckless — and the patient receiving the vial generally cannot tell the difference from the outside.

What FDA compliance actually means

When we say a compounding pharmacy sources from FDA-compliant facilities, we mean the active pharmaceutical ingredient — the semaglutide or tirzepatide itself — was manufactured under conditions the FDA oversees. Specifically:

• FDA-registered facilities are on record with the agency and subject to inspection. This is the baseline. A facility that isn't registered has no formal accountability to U.S. regulators.
• cGMP — current Good Manufacturing Practice — is the manufacturing standard that governs how drugs are made, tested, and controlled. It covers equipment, processes, documentation, and quality systems. A cGMP facility isn't just making the molecule; it's making it consistently, to a documented standard, with records that can be audited.

These two requirements together are what separate a pharmaceutical-grade bulk ingredient from a research-grade or unregulated one. The molecule may look identical. The controls behind it are not.

Why the pharmacy matters as much as the ingredient

A high-quality bulk ingredient can still produce a poor or dangerous compounded product if the pharmacy preparing it doesn't meet sterile compounding standards. For injectable GLP-1 medications, the relevant standard is USP <797> — the framework for sterile preparation that governs clean rooms, beyond-use dating, testing protocols, and environmental monitoring.

A pharmacy that cuts corners on sterile preparation introduces contamination risk regardless of where the API came from. Both ends of the supply chain have to be right.

The vial you receive is only as good as every decision made before it was filled.

Independent third-party testing

Even with FDA-registered API sources and cGMP manufacturing, independent third-party testing is the final verification layer. It confirms that what the label says is in the vial is actually in the vial — in the right amount, without contaminants, at the right sterility level. It is not a formality. It is the check that catches failures the supply chain itself missed.

This is why we require it of our pharmacy partners, and why we say so explicitly. A practice that doesn't mention its testing standards either hasn't thought about them or would prefer you didn't ask.

What this means for your protocol

When a board-certified physician prescribes a compounded GLP-1 through Zashel, the sourcing chain behind that prescription has been vetted — FDA-registered API, cGMP manufacturing, USP <797> sterile preparation, and independent third-party testing. You don't have to audit it yourself. That is part of what you are paying for.

This entry is educational and reflects the standards Zashel holds for its pharmacy partners. It is not legal or medical advice.